LTP·01learntopeptide
Cognitive & neuroPeptideEvidence B4 cited

Selank

Anxiolytic Nootropic Peptide

aka TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro · anxiolytic peptide

A synthetic tuftsin-derived peptide researched for anxiety reduction and cognitive enhancement without sedation.

Molecular wt
751.9g/mol
Formula
C33H57N11O9
CAS
129954-34-3
Half-life
30 min
clinical
Tmax
30 min
Route
Intranasal (also subcutaneous)
PubChem
11765600

Sequence

One-letter7 residues

TKPRPGP

Three-letter

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Read this before quoting the sequence
Heptapeptide: the tuftsin fragment Thr-Lys-Pro-Arg extended C-terminally with Pro-Gly-Pro. PubChem lists 'Thr-Lys-Pro-Arg-Pro-Gly-Pro' as a synonym of CID 11765600.
Source ↗

Mechanism of action

Selank is a synthetic peptide that mimics the effects of the naturally occurring tuftsin, which is involved in immune modulation. It works by influencing the balance of neurotransmitters in the brain, particularly serotonin and dopamine, which are crucial for mood regulation. Selank also enhances the expression of brain-derived neurotrophic factor (BDNF), supporting neuronal growth and synaptic plasticity.

What the evidence actually shows

Grade B

There are several human trials conducted in Russia that suggest Selank is effective in reducing anxiety and improving cognitive function. However, these studies are limited in number and often lack rigorous controls. More extensive, placebo-controlled trials are needed to confirm these findings. | REGULATORY: FDA Category 2 reclassification to Category 1 expected (announced Feb 2026).

Regulatory status

Status
Not approved as a medicine by FDA or EMA. Described in the peer-reviewed literature as a Russian drug sold to US consumers as a dietary supplement.
Clinical stage
No Western registrational programme identified; human data are limited to Russian-language studies.
UK
research_compound

In the UK, Selank is not approved for medical use and is considered a research compound. It is not licensed by the MHRA.

Source ↗

Pharmacokinetics

Half-life
30 min
Tmax
30 min
Absorption
subcutaneous
Elimination
renal
Washout
1 days
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

Selank has been studied in humans - Russian-language randomized comparisons against phenazepam in generalized anxiety disorder and neurasthenia are indexed in PubMed (PMIDs 18454096, 25176261, 18577961) - but none of those abstracts state a dose, and no approved FDA/EMA/MHRA label exists. The only dose that could be sourced is preclinical: 300 mcg/kg intranasally in rats.

PreclinicalAnimal studies — not a human dose

  • 300 micrograms/kg as a single intranasal administration (6 microlitres of aqueous solution)

    male Wistar rat · intranasal · PMID 26924987

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

Commonly circulatedNot established by any study
Dose
Research literature cites intranasal ~250 to 500 mcg/day
Frequency
1-3x daily

Why this isn't evidence
No source read in this pass documents a human dose of any size for Selank, so the specific 250-500 mcg/day range cannot be attributed to 'research literature'; the only sourced number, 300 mcg/kg, is a rat intranasal dose that would scale to roughly 20 mg in a 70 kg adult, not 0.25-0.5 mg.

This figure is shown because it is what circulates and what people search for — not because it is supported. Cycle lengths in particular tend to be convention copied between compounds rather than anything derived from a compound's own pharmacokinetics.

No established human dose
No approved label or completed human trial establishes a dosing regimen for this compound. Anything presented as a standard protocol for it — anywhere — is someone's convention rather than a finding.

Handling and storage

No compound-specific stability data exists
No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Selank has no FDA or EMA label; no peer-reviewed stability study was located. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Commonly reported
  • ·Mild headache
  • ·Nasal irritation
Rarely reported
  • ·Allergic reactions
Contraindications
  • ·Pregnancy
  • ·Breastfeeding
  • ·"Severe psychiatric disorders"
Drug interactions
  • ·MAO inhibitors: Potential for increased serotonin levels

Generally well tolerated in studies

Reported combinations

Reported as synergistic
  • ·L-theanine
  • ·Ashwagandha
Reported as antagonistic
  • ·Alcohol: May reduce efficacy

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (4)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage, reconstitution, regulatory.wada, regulatory.russianApproval

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Cognitive & neuro

ARA-290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR) without stimulating erythropoiesis. Provides neuroprotection, anti-inflammatory, and tissue repair effects.
CAQK
Brain-injury-homing tetrapeptide targeting chondroitin sulfate proteoglycans at injury sites.
Cerebrolysin
A porcine-derived neuropeptide complex researched for neuroprotection, cognitive recovery, and stroke rehabilitation.